TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06612268: A Global Phase 3, Randomised, Double-blind and Placebo-controlled Study Evaluating the Efficacy and Safety of Etavopivat in Adolescents and Adults With Sickle Cell Disease

Sponsor: Novo Nordisk A/S · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 510 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$565,728

Rescue Site Savings

+$377,152

Unlock Full NCT06612268 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06612268 Rescue Dossier →